Researchers are examining how next-generation sequencing could change newborn screening, according to a review published in Pediatric Investigation on Mar. 16. The study explores the potential for genomic methods to complement traditional biochemical tests and expand the range of conditions detected at birth.
Newborn screening programs currently use biochemical markers to identify treatable inherited disorders before symptoms appear. While these programs have been successful, there is growing concern that they may not be sufficient as more genetically driven diseases are discovered.
Dr. Zhelan Huang from the Children's Hospital of Fudan University and Dr. Wenhao Zhou from Guangzhou Women and Children's Medical Center reviewed how next-generation sequencing (NGS) might transform newborn screening by enabling multi-disease detection through genome analysis. Their research highlights both the opportunities and challenges of implementing genomic newborn screening (gNBS). Dr. Zhou said, "Conventional NBS methods are inherently constrained by their reliance on measurable biochemical abnormalities. While effective for disorders like phenylketonuria or congenital hypothyroidism, many genetic diseases do not produce detectable metabolic signals during the neonatal period. Consequently, affected infants appear healthy at birth but develop symptoms after irreversible damage has already occurred." He added that genetic screening offers a direct way to detect disease risk early.
gNBS uses DNA from dried blood spots collected during routine screening and applies targeted gene panels, whole-exome sequencing, or whole-genome sequencing to assess multiple genes linked to inherited disorders. This approach can identify conditions missed by traditional testing but also introduces new complexities such as interpreting variants of uncertain significance and managing ethical concerns about reporting findings with unclear clinical impact.
The turnaround time for genomic results is another challenge; while conventional tests provide answers within days, genomic sequencing may take weeks—limiting its usefulness for urgent cases. Dr. Zhou said, "A major research focus is reducing the turnaround time for genetic screening through rapid whole-genome sequencing approaches, which are already being applied in some critically ill infants. Although these approaches are not yet used in routine population screening, continued efforts may broaden their application in the future." He also noted ongoing debates about psychological impacts on families and ethical questions regarding consent and data storage.
Dr. Zhou said, "Driven by lower costs, technological advances, and supportive policy frameworks, gNBS is expected to gradually integrate with or even evolve into a standardized tool for newborn healthcare management ." The researchers conclude that while technical and ethical challenges remain, genomic newborn screening could lead to more precise identification of inherited diseases and support long-term health planning.
